ANNOUNCEMENT {#s1}
============

The J-Lat 10.6 cell line is a subclone derived from Jurkat-based cells infected with a pseudotyped human immunodeficiency virus type 1 (HIV-1) (genus *Lentivirus*, family *Retroviridae*) strain, HIV/R7/E^−^/GFP ([@B1], [@B2]). The integrated HIV-1 copy in this cell line is located in the second intron of *SEC16A* (chromosome 9, position 136468579), providing a useful cell line for studying HIV-1 latency ([@B3]). In order to use J-Lat 10.6 for anti-HIV-1 gene editing and design strategies using the clustered regularly interspaced short palindromic repeats (CRISPR) system, it is necessary to have the full proviral DNA sequence ([@B4][@B5][@B11]). However, the full-length sequence of integrated HIV/R7/E^−^/GFP has not been reported. Here, we amplified two overlapping fragments and performed subsequent Sanger sequencing to acquire the whole genome of HIV/R7/E^−^/GFP.

Genomic DNA was isolated from J-Lat 10.6 cells utilizing the QIAamp DNA minikit (catalog number 51304; Qiagen) as described by the manufacturer. In order to determine the HIV-1 proviral sequence, the DNA was amplified as two fragments using newly designed primers ([Table 1](#tab1){ref-type="table"}). The amplicon starting at the 5′ end of the provirus (5′ amplicon) was 8,999 bp and was amplified using primers based on the reported integration site ([@B3]); primers 10.6_up5LTR_F and eGFP-N (ReadyMade Primers, catalog number 51-01-05-05; Integrated DNA Technologies), directed to the N terminus of the gene for enhanced green fluorescent protein (eGFP), which replaces *nef* in this molecular clone, were used for the 5′ amplicon PCR. An adapted single-genome amplification protocol ([@B12]) using Platinum *Taq* polymerase (catalog number 10966026; Invitrogen) was implemented.

###### 

Primers utilized for amplification and sequencing, including primer locations within the proviral genome and human genome, directionality, and sequences

  Primer type and name                                         Sequence                   Genome               Nucleotide position   Strand      Length (bp)   
  ------------------------------------------------------------ -------------------------- -------------------- --------------------- ----------- ------------- ----
  Amplification                                                                                                                                                
      10.6_up5LTR_F[^*a*^](#ngtab1.1){ref-type="table-fn"}     CGTACTGGCTGGAGTAATAGCT     hg38, chromosome 9   136468424             136468445   \+            22
      eGFP-N[^*a*^](#ngtab1.1){ref-type="table-fn"}            CGTCGCCGTCCAGCTCGACCAG     HIV                  8776                  8797        −             22
      Frag-26-R-RC[^*b*^](#ngtab1.2){ref-type="table-fn"}      CTGGCTGTGGAAAGATACCT       HIV                  7983                  8002        \+            20
      10.6_down3LTR_R[^*b*^](#ngtab1.2){ref-type="table-fn"}   GAATGCCCATTGCTTTGGGAA      hg38, chromosome 9   136468587             136468607   −             21
  Sequencing                                                                                                                                                   
      10.6_up5LTR_F                                            CGTACTGGCTGGAGTAATAGCT     hg38, chromosome 9   136468424             136468445   \+            22
      10.6_down3LTR_R                                          GAATGCCCATTGCTTTGGGAA      hg38, chromosome 9   136468587             136468607   −             21
      275F                                                     ACAGGGACCTGAAAGCGAAAG      HIV                  646                   666         \+            21
      275F-RC                                                  CTTTCGCTTTCAGGTCCCTGT      HIV                  646                   666         −             21
      Frag-22-R                                                GGGTAATTTTGGCTGACCTG       HIV                  1168                  1187        −             20
      Frag-22-R-RC                                             CAGGTCAGCCAAAATTACCC       HIV                  1168                  1187        \+            20
      Frag-14-R                                                ATGTCACTTCCCCTTGGTTC       HIV                  1477                  1496        −             20
      Frag-14-R-RC                                             GAACCAAGGGGAAGTGACAT       HIV                  1477                  1496        \+            20
      Frag-17-L                                                GGAAATGTGGAAAGGAAGGAC      HIV                  2030                  2050        \+            21
      Frag-17-L-RC                                             GTCCTTCCTTTCCACATTTCC      HIV                  2030                  2050        −             21
      Frag-25-L                                                TGGATGGCCCAAAAGTTAAAC      HIV                  2596                  2616        \+            21
      Frag-33-R-RC                                             CACAGGGATGGAAAGGATCA       HIV                  2998                  3017        \+            20
      5INOut                                                   ACTCCATCCTGATAAATGGACAG    HIV                  3248                  3270        \+            23
      Frag-10-L                                                ACAATTAACAGAGGCAGTGC       HIV                  3647                  3666        \+            20
      Frag-18-L                                                AGTGATTTTAACCTGCCACC       HIV                  4299                  4318        \+            20
      Frag-27-L                                                TGGTAGCAGTTCATGTAGCC       HIV                  4450                  4469        \+            20
      5AccOut                                                  CGGGTTTATTACAGGGACARCARA   HIV                  4899                  4922        \+            24
      3InOut-RC                                                GGCAAGTAGACAGGATGAGGATT    HIV                  5072                  5094        \+            23
      Frag-37-L                                                AAAGCCACCTTTGCCTAGTG       HIV                  5517                  5536        \+            20
      Frag-36-R                                                CTGACTTCCTGGATGCTTCC       HIV                  5862                  5881        −             20
      Frag-36-R-RC                                             GGAAGCATCCAGGAAGTCAG       HIV                  5862                  5881        \+            20
      Frag-05-L                                                AGCAGAAGACAGTGGCAATG       HIV                  6208                  6227        \+            20
      3AccOut-RC                                               ATAATRTYTGGGCCACACATGCC    HIV                  6421                  6443        \+            23
      Frag-09-L                                                TGGCAGTCTAGCAGAAGAAG       HIV                  7010                  7029        \+            20
      Frag-39-L                                                CAATGTATGCCCCTCCCATC       HIV                  7522                  7541        \+            20
      Frag-26-R-RC                                             CTGGCTGTGGAAAGATACCT       HIV                  7965                  7984        \+            20
      Frag-21-L                                                GAAGGTGGAGAGAGAGACAG       HIV                  8430                  8449        \+            20
      eGFP-N                                                   CGTCGCCGTCCAGCTCGACCAG     HIV                  8776                  8797        −             22
      eGFP-C                                                   CATGGTCCTGCTGGAGTTCGTG     HIV                  9517                  9538        \+            22
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Primers used for the 5′ amplicon (8,999 bp), with the following PCR conditions: 94°C for 2 min, (94°C for 30 s, 62°C for 30 s, and 68°C for 10 min) for 3 cycles, (94°C for 30 s, 58°C for 30 s, and 68°C for 10 min) for 3 cycles, (94°C for 30 s, 56°C for 30 s, and 68°C for 10 min) for 3 cycles, (94°C for 30 s, 53.5°C for 30 s, and 68°C for 10 min) for 21 cycles, and 68°C for 10 min.

Primers used for the 3′ amplicon (2,140 bp), with the following PCR conditions: 98°C for 1 min, (98°C for 10 s, 68.8°C for 20 s, and 72°C for 1 min) for 30 cycles, and 72°C for 1 min.

The 3′ amplicon encompassed eGFP and the 3′ long terminal repeat (LTR) and was 2,140 bp. It was amplified using primers Frag-26-R-RC and 10.6_down3LTR_R, with the PCR conditions listed in [Table 1](#tab1){ref-type="table"}. The PCR products were enzymatically purified utilizing ExoSAP-IT PCR product cleanup reagent (catalog number 78201.1.ML; Thermo Fisher Scientific). Sanger sequencing was performed by GENEWIZ, Inc. (South Plainfield, NJ), using Applied Biosystems BigDye version 3.1 and the primers listed in [Table 1](#tab1){ref-type="table"}. The reactions were run on an Applied Biosystems 3730xl DNA analyzer.

Quality control of the sequence was performed by end trimming using average quality scores of \>16 over 21 bp, followed by assembly with default settings in DNASTAR SeqMan ([@B13]). The entire HIV-1 proviral genome reported was 10,200 bp, with a GC content of 43.7%. Every nucleotide within HIV/R7/E^−^/GFP was sequenced at least twice for a high level of accuracy and was annotated by DNASTAR SeqBuilder for GenBank submission ([@B13]). Previously reported mutations in *vpr* and *env* and the resulting immature proteins were annotated in the GenBank file ([@B2], [@B14]). There is an insertion of thymine and adenine at nucleotide position 6548, which causes a frameshift of *env* and an early stop codon at amino acid residue 85. The *vpr* coding region has an insertion of thymine at nucleotide position 5919, which causes a frameshift of *vpr* and an early stop codon at Vpr amino acid residue 79.

Data availability. {#s1.1}
------------------

The accession number for the genome sequence of HIV/R7/E^−^/GFP and the flanking integration site is [MN989412](https://www.ncbi.nlm.nih.gov/nuccore/MN989412).
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